lutetium has been researched along with Androgen-Independent Prostatic Cancer in 174 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 56 (32.18) | 24.3611 |
| 2020's | 118 (67.82) | 2.80 |
| Authors | Studies |
|---|---|
| Bartholomä, M; Ezziddin, S; Ghazal, Z; Khreish, F; Linxweiler, J; Marlowe, RJ; Maus, S; Rosar, F; Sabet, A | 1 |
| Kim, YI; Lee, DY | 1 |
| Hindié, E | 1 |
| Ahmed, N; Al Kandari, F; Alrekhais, I; N Khalaf, S; Usmani, S | 1 |
| Akgun, E; An, F; Aras, O; Beytur, F; Bilgic, S; Gulsen, F; Oklu, R; Sager, S; Sayman, HB; Toplutas, KN; Yeyin, N | 1 |
| Frydenberg, M; Grimes, D; McBean, R; Vasey, P; Wong, D; Yaxley, JW; Yaxley, WJ | 1 |
| Barentsz, JO; Bergman, AM; de Groot, M; Gerritsen, WR; Gotthardt, M; Janssen, MJR; Jonker, MA; Mehra, N; Muselaers, CHJ; Nagarajah, J; Noordzij, W; Oprea-Lager, DE; Privé, BM; Scheenen, TWJ; van der Poel, HG; van Gemert, WA; van Oort, IM; Verzijlbergen, JF; Vis, AN; Vogel, WV; Westdorp, H; Witjes, JA; Zámecnik, P | 1 |
| Mumtaz, M; Shahid, A; Sheikh, N; Younis, MN | 1 |
| Amoui, M; Deevband, MR; Ghorbani, M; Mahmoudi, E; Pirayesh, E; Rad, MG | 1 |
| Afshar-Oromieh, A; Birindelli, G; D'Alessandria, C; Drobnjakovic, M; Eiber, M; Gourni, E; Morath, V; Rominger, A; Shi, K; Steiger, K; Weber, W | 1 |
| Xin, P; Zhang, H; Zhang, YX | 1 |
| Drzezga, A; Fischer, T; Hammes, J; Heidenreich, A; Pfister, D; Schmidt, M; Schneider, CA; Täger, P | 1 |
| Ali, S; Castellucci, P; Farolfi, A; Mei, R | 1 |
| Baumgarten, J; Bockisch, B; Gröner, D; Grünwald, F; Happel, C; Kranert, WT; Nguyen Ngoc, LQC; Sabet, A; Wichert, J | 1 |
| Chandran, E; Figg, WD; Madan, R | 1 |
| Byun, Y; Cai, X; Duan, X; Fan, Y; Ha, H; Liu, Z; Wang, Y; Xu, H; Yang, X; Yang, Z; Zhang, J; Zhang, T | 1 |
| Byrd, A; Curtis, J; Hicklin, D; Mascari, R; Nichols, C; Orofino, C; Sen, S; Vezzeti, A | 1 |
| Gorin, MA; Pienta, KJ; Pomper, MG; Rowe, SP; Sadaghiani, MS; Sheikhbahaei, S; Solnes, LB; Werner, RA | 1 |
| Gill, HJS; Maheshwari, P; Satapathy, S; Sharma, A; Sood, A | 1 |
| Bruchertseifer, F; Hlongwa, KN; Knoesen, O; Lawal, IO; Mahapane, J; Maserumule, LC; Mdlophane, A; Mokoala, KMG; Morgenstern, A; Ndlovu, H; Popoola, GO; Reed, JD; Sathekge, MM; Vorster, M | 1 |
| Basaran, M; Has Simsek, D; Isik, EG; Karadogan, S; Kuyumcu, S; Ozkan, ZG; Sanli, MO; Sanli, Y | 1 |
| Keam, SJ | 1 |
| de Blois, E; de Jong, M; De Saint-Hubert, M; Konijnenberg, MW; Nonnekens, J; Roobol, SJ; Ruigrok, EAM; Tamborino, G; van Weerden, WM; Verkaik, N | 1 |
| Calais, J; Gafita, A; Hofman, MS; Kostos, L; Marcus, C; Schuster, DM | 1 |
| Sartor, O | 1 |
| Herrmann, K; Sartor, O | 1 |
| Böger, CA; Büttner-Herold, M; Eiber, M; Gschwend, JE; Heemann, U; Knorr, K; Mayr, S; Schäfer, H; Schmaderer, C; Steinhelfer, L; Tauber, R | 1 |
| Bjartell, A; Fanti, S; Kunikowska, J; Walz, J; Witjes, W | 1 |
| Chandrashekar, R; Fagan, J; Lim, R; Vyas, M | 1 |
| Aschenbrenner, DS | 1 |
| Armstrong, WR; Benz, MR; Calais, J; Eiber, M; Fendler, WP; Gafita, A; Herrmann, K; Hui, W; Murthy, V; Rauscher, I; Weber, M; Weber, WA | 1 |
| Amini, H; Aryana, K; Divband, G; Manafi-Farid, R; Moghadam, SZ | 1 |
| Caliebe, A; Jüptner, M; Lützen, U; Marx, M; Osmonov, D; Wrenger, R; Zhao, Y; Zuhayra, M | 1 |
| Buck, AK; Bundschuh, RA; Essler, M; Hartrampf, PE; Kosmala, A; Kübler, H; Seitz, AK; Serfling, SE; Weinzierl, FX; Werner, RA | 1 |
| Buck, AK; Bundschuh, RA; Essler, M; Hartrampf, PE; Kübler, H; Seitz, AK; Weinzierl, FX; Werner, RA | 1 |
| Olivier, T; Powell, K; Prasad, V | 1 |
| Garje, R; Parikh, RA; Rumble, RB | 1 |
| Grubmüller, B; Hacker, M; Haug, AR; Kramer, G; Kretschmer-Chott, E; Mitterhauser, M; Oszwald, A; Rasul, S; Shariat, SF; Vraka, C; Wollenweber, T; Yu, J; Zisser, L | 1 |
| D'Alessandria, C; Eiber, M; Haller, B; Heck, M; Karimzadeh, A; Knorr, K; Rauscher, I; Tauber, R; Weber, WA | 1 |
| Bassi, G; Cazzamalli, S; Favalli, N; Georgiev, T; Lucaroni, L; Manz, MG; Neri, D; Oehler, S; Pellegrino, C; Prati, L; Prodi, E; Puglioli, S | 1 |
| Aggarwal, P; Das, CK; Mittal, BR; Parihar, AS; Satapathy, S; Singh, SK; Sood, A | 1 |
| Bundschuh, RA; Dittmann, H; Eiber, M; Essler, M; Fendler, WP; Fougère, C; Hasa, E; Kurtinecz, M; Pabst, KM; Prasad, V; Rahbar, K; Rassek, P; Sartor, O; Schmall, A; Verholen, F | 1 |
| Jacene, H; Ravi, P; Shah, H; Sonpavde, G | 1 |
| Chen, X; Fan, X; Jiang, Y; Liu, Q; Sui, H; Wang, G; Wang, R; Zang, J; Zhang, J; Zhu, Z | 1 |
| Agrawal, S; Amiri-Kordestani, L; Chen, W; Chiang, K; Fallah, J; Fiero, MH; Fotenos, A; Gittleman, H; Ibrahim, A; John, C; Kluetz, PG; Niu, G; Pazdur, R; Pierce, WF; Ricks, TK; Subramaniam, S; Suzman, DL; Tang, S; Wang, M | 1 |
| Blais, A; Morrison, H; Murtha, N; Quirk, S; Roumeliotis, M; Smith, W | 1 |
| Bartenstein, P; Beyer, L; Froelich, MF; Herlemann, A; Kramer, KKM; Kunz, WG; Mehrens, D; Ricke, J; Rübenthaler, J; Schmidt-Hegemann, NS; Tollens, F; Unterrainer, LM; Unterrainer, M | 1 |
| Amurao, M; Baumann, BC; Garcia-Ramirez, J; Gay, HA; Luechtefeld, D; Maughan, NM; Michalski, JM; Oyama, R; Zoberi, JE | 1 |
| Garje, R; Hope, TA; Parikh, RA; Rumble, RB | 1 |
| Karnes, RJ; Kemble, J; Kwon, ED | 1 |
| Choudhury, AD; Jacene, H; Kelly, E; Kilbridge, KL; Morgans, AK; Pomerantz, M; Ravi, P; Ritzer, J; Robertson, M; Shah, H; Sunkara, R; Taplin, ME; Wei, XX; Whelpley, B; Wolanski, A | 1 |
| Baumgarten, J; Chun, FKH; Groener, D; Grünwald, F; Happel, C; Kirkgöze, B; Klimek, K; Mader, N; Nguyen Ngoc, C; Sabet, A; Tselis, N | 1 |
| de Feijter, JM; Seijkens, TTP; van Golen, LW; Vogel, W | 1 |
| Aggarwal, P; Kaur, K; Mittal, BR; Nagi, S; Periasamy, K; Sood, A | 1 |
| Burgard, C; Ezziddin, S; Khreish, F; Maus, S; Rosar, F; Schaefer-Schuler, A | 1 |
| Ramnaraign, B; Sartor, O | 1 |
| Chen, ZS; Fang, GC; Han, CH; Liu, X; Lu, H; Shi, ZD | 1 |
| Jacobs, N; More, S; Naiker, T; Oompie, F; Prasad, V | 1 |
| Benz, MR; Burger, IA; Calais, J; Czernin, J; Eiber, M; Emmett, L; Farolfi, A; Fendler, WP; Gafita, A; Hofman, MS; Hope, TA; Hotta, M; Kratochwil, C; Murthy, V; Sonni, I; Weber, MM | 1 |
| Roulleaux Dugage, M; Schlürmann, F | 1 |
| Aragon-Ching, JB; Atiq, M; Chandran, E; Karzai, F; Madan, RA | 1 |
| Bauder-Wüst, U; Benešová-Schäfer, M; Breyl, H; Poethko, T; Remde, Y; Roscher, M; Schäfer, M; Tömböly, C; Winter, R | 1 |
| Bal, C; Sahoo, RK; Satapathy, S | 1 |
| Baum, RP; Bodei, L; Bozkurt, MF; Calais, J; Delgado Bolton, RC; Eiber, M; Emmett, L; Ezziddin, S; Fanti, S; Fendler, WP; Forrer, F; Haberkorn, U; Hermann, K; Hicks, RJ; Hofman, MS; Hope, TA; Iravani, A; Kabasakal, L; Konijnenberg, M; Koo, P; Kopka, K; Kratochwil, C; Lassmann, M; Lindenberg, L; Mottaghy, FM; Osborne, JR; Oyen, WJG; Rahbar, K; Schoder, H; Virgolini, I | 1 |
| D'Alessandria, C; Eiber, M; Haller, B; Heck, M; Karimzadeh, A; Knorr, K; Nekolla, S; Rauscher, I; Solaris, E; Tauber, R; Weber, WA | 1 |
| Antonarakis, ES; Bodei, L; Calais, J; Hope, TA; Iravani, A; Jacene, H; Koo, PJ; Morgans, AK; Morris, MJ; Osborne, JR; Sartor, O; Tagawa, ST; Taplin, ME | 1 |
| D'Alessandria, C; Eiber, M; Grigorascu, S; Gschwend, J; Hansen, K; Knorr, K; Langbein, T; Rauscher, I; Retz, M; Tauber, R; Weber, W; Wester, HJ | 1 |
| Allen-Auerbach, M; Calais, J; Czernin, J; Lam, R; Murthy, V; Owen, D | 1 |
| Bastick, P; Clifton-Bligh, R; Counter, W; Crumbaker, M; Emmett, L; Harvey, C; John, N; Kumar, S; Lee, A; McDonald, MM; Nguyen, A; Pathmanandavel, S; Swiha, MM | 1 |
| Ardolino, LC; Armstrong, AJ; Dear, R; Gillessen, S; Joshua, AM | 1 |
| Artigas, C; Flamen, P; Gil, T; Guiot, T; Karfis, I; Martinez-Chanza, N; Roumeguere, T; Shagera, QA; Sideris, S; Woff, E | 1 |
| de Bakker, M; Dominicus, N; Janssen, M; Konijnenberg, MW; Meeuwis, A; Nagarajah, J; Peters, SMB | 1 |
| Fatima, A; Fatima, I; Khan, IU; Parveen, A; Shahid, A | 1 |
| Bal, C; Ballal, S; Damle, NA; Raju, S; Sahoo, RK; Satapathy, S; Tripathi, M; Yadav, MP | 1 |
| Bley, T; Buck, AK; Bundschuh, RA; Cytawa, W; Hartrampf, PE; Hendel, R; Jassem, J; Lapa, C; Schirbel, A; Tomasik, B; Weinzierl, FX; Werner, RA | 1 |
| Aggarwal, P; Kumar, S; Mahdi, RA; Mittal, BR; Paul, D; Sood, A | 1 |
| Das, CK; Goyal, S; Mavuduru, RS; Mittal, BR; Satapathy, S; Shukla, J; Singh, SK; Sood, A | 1 |
| Barata, P; Harris, K; Hawkins, M; Huang, M; Jang, A; Lanka, S; Layton, J; Ledet, E; Lewis, B; Lieberman, A; Pocha, O; Sartor, O; Schwartz, J | 1 |
| Chen, Y; Su, D; Yang, H; Zhang, Y | 1 |
| Freesmeyer, M; Leder, T; Seifert, P; Theis, B; Werner, A | 1 |
| Bavbek, S; Demirkol, MO; Esen, B; Esen, T; Falay, O; Kurtuldu, S; Mandel, NM; Şen, M; Seymen, H; Tilki, D; Uçar, B | 1 |
| Bakkal Temi, Y; Cabuk, D; Can Sanci, P; Karakayali, A; Kefeli, U; Ozkorkmaz Akdag, M; Şahin, E; Seyyar, M; Ucuncu Kefeli, A; Uygun, K; Zorlu, Ş | 1 |
| Banerjee, SR; Boinapally, S; Brayton, C; Brummet, M; Chen, J; Cole, M; Hobbs, RF; Kumar, V; Lisok, A; Minn, I; Ngen, E; Pomper, MG; Wharram, B | 1 |
| Boegemann, M; Kessel, K; Rahbar, K; Schäfers, M; Schlack, K; Seifert, R; Weckesser, M | 1 |
| Akhurst, T; Hicks, RJ; Hofman, MS; Iravani, A; Kong, G; Murphy, DG; Ravi Kumar, A; Sandhu, S; Thang, SP; Violet, J; Williams, SG | 1 |
| Afshar-Oromieh, A; Alberts, I; Rominger, A; Sachpekidis, C | 1 |
| Ahmadzadehfar, H; Brossart, P; Essler, M; Feldmann, G; Fimmers, R; Hauser, S; Holdenrieder, S; Linden, P; Yordanova, A | 1 |
| Baum, RP; Liu, C; Liu, T; Yang, Z; Zhang, J | 1 |
| Beer, AJ; Eiber, M; Glatting, G; Kletting, P; Rinscheid, A | 1 |
| Bakshi, G; Banerjee, S; Basu, S; Joshi, A; Parghane, RV; Prabhash, K; Suman, S; Talole, S | 1 |
| Boegemann, M; Kessel, K; Köhler, M; Rahbar, K; Roll, W; Seifert, R; Stegger, L; Weckesser, M | 1 |
| Araz, M; Kucuk, NO; Nak, D; Ozkan, E; Soydal, C; Urun, Y | 1 |
| Bal, C; Ballal, S; Damle, NA; Sahoo, RK; Seth, A; Tripathi, M; Yadav, MP | 2 |
| Demirkol, MO; Falay, FO; Özkan, A; Seymen, H; Uçar, B; Yildiz Yarar, Y | 1 |
| Cala, L; D'Alessandria, C; Eiber, M; Franz, C; Gafita, A; Heck, MM; Rauscher, I; Retz, M; Tauber, R; Weber, WA | 1 |
| Akhurst, T; Ferdinandus, J; Hicks, RJ; Hofman, MS; Iravani, A; Kong, G; Murphy, DG; Ravi Kumar, AS; Sandhu, S; Thang, SP; Violet, J; Williams, S | 1 |
| Joensuu, T; Kairemo, K; Kangasmäki, A; Seregard, S | 1 |
| Bengel, FM; Derlin, T; Henkenberens, C; Lafos, M; Ross, TL; Sommerlath Sohns, JM; von Klot, CAJ; Werner, RA | 1 |
| Bengel, FM; Derlin, T; Henkenberens, C; Ross, TL; Schmuck, S; Sommerlath Sohns, JM; von Klot, CAJ | 1 |
| Bögemann, M; Herrmann, K; Radtke, JP; Rahbar, K | 1 |
| Aharon, M; Ben-Haim, S; Berger, R; Davidson, T; Domachevsky, L; Gadot, M; Leibowitz, R; Levartovsky, M; Malki, A; Oedegaard, C; Saad, A; Sandler, I | 1 |
| Calais, J; Czernin, J; Delpassand, ES; Eiber, M; Esfandiari, R; Fendler, WP; Gafita, A; Herrmann, K; Hofman, MS; Hui, W; Rathke, H; Rauscher, I; Sandhu, S; Tauber, R; Weber, M; Weber, WA | 1 |
| Barna, S; Blaickner, M; Grubmüller, B; Hartenbach, M; Haug, AR; Kramer, G; Rasul, S | 1 |
| Aryana, K; Askari, E; Divband, G; Moghadam, SZ | 1 |
| Cordes, M; Götz, TI; Kuwert, T; Lang, EW; Ludwig, B; Prante, O; Ritt, P; Schmidkonz, C | 1 |
| Boegemann, M; Herrmann, K; Kessel, K; Kleesiek, J; Rahbar, K; Schäfers, M; Seifert, R; Seitzer, K; Weckesser, M | 1 |
| Azad, AA; Chan, L; Crumbaker, M; Danesh, A; Emmett, L; Ende, JA; Eu, P; Ho, B; Joshua, AM; Keane, J; Kongrak, K; Kwan, EM; Nguyen, A; Pathmanandavel, S; Pugh, TJ; Rofe, C; Sharma, S; Yam, AO | 1 |
| Babu Koyyala, VP; Choudhury, PS; Gupta, M; Jain, P; Karthikeyan, G; Rawal, S; Sharma, M; Singh, A; Talwar, V | 1 |
| Mittal, BR; Satapathy, S; Sood, A | 1 |
| Armstrong, AJ; George, DJ; Harrison, MR; Hoimes, CJ; Kao, C; Karachaliou, GS; Powers, E; Zhang, T | 1 |
| Grubmüller, B; Hacker, M; Hartenbach, M; Haug, AR; Kramer, G; Kretschmer-Chott, E; Mitterhauser, M; Pichler, V; Rasul, S; Shariat, S; Vraka, C; Wadsak, W; Wollenweber, T | 1 |
| Grobbee, DE; Hehakaya, C; Lam, MGEH; Moors, EHM; Verburg, FA; Verkooijen, HM | 1 |
| Beheshti, A; Bruchertseifer, F; D'Alessandria, C; Eiber, M; Feuerecker, B; Gafita, A; Gschwend, JE; Heck, M; Knorr, K; Kratochwil, C; Morgenstern, A; Pickhard, A; Retz, M; Seidl, C; Tauber, R; Weber, WA | 1 |
| Amthauer, H; Brenner, W; De Santis, M; Erber, B; Huang, K; Lindquist, RL; Radojewski, P; Rogasch, JMM; Schatka, I | 1 |
| Das, CK; Mittal, BR; Parihar, AS; Satapathy, S; Sood, A | 1 |
| Gorin, MA; Pienta, KJ; Pomper, MG; Rowe, SP; Sadaghiani, MS; Sheikhbahaei, S; Solnes, LB; Wang, NY; Werner, RA | 1 |
| Bal, C; Ballal, S; Damle, NA; Kumar, R; Sahoo, RK; Seth, A; Shamim, SA; Tripathi, M; Yadav, MP | 1 |
| Gericke, G | 1 |
| Armour, A; Beer, TM; Chi, KN; de Bono, J; DeSilvio, M; El-Haddad, G; Fizazi, K; Gericke, G; Herrmann, K; Kpamegan, E; Krause, BJ; Messmann, RA; Morris, MJ; Nordquist, LT; Park, CH; Pérez-Contreras, WJ; Rahbar, K; Sartor, O; Tagawa, ST; Vaishampayan, N | 1 |
| Hadaschik, B; Herrmann, K | 1 |
| Calais, J; Czernin, J | 1 |
| Attard, G; Calistri, D; Casadei, C; Celli, M; Conteduca, V; De Giorgi, U; Di Iorio, V; Foca, F; Gurioli, G; Matteucci, F; Monti, M; Nicolini, S; Paganelli, G; Sansovini, M; Severi, S; von Eyben, FE | 1 |
| Ahmadzadehfar, H; Eppard, E; Essler, M; Fimmers, R; Hauser, S; Kürpig, S; Schlenkhoff, C; Wegen, S; Wei, X; Yordanova, A | 1 |
| Bögemann, M; Bräuer, A; Grubert, LS; Rahbar, K; Roll, W; Schäfers, M; Schrader, AJ | 1 |
| Ahmadzadehfar, H; Essler, M; Schlenkhoff, C; Schwarz, B; Wei, X | 1 |
| Boegemann, M; Rahbar, K; Schrader, AJ | 1 |
| Ahmadzadehfar, H; Boegemann, M; Essler, M; Eveslage, M; Rahbar, K; Schäfers, M; Yordanova, A | 1 |
| Ahmadzadehfar, H; Bögeman, M; Essler, M; Eveslage, M; Rahbar, K; Schäfers, M; Yordanova, A | 1 |
| Ahmadzadehfar, H; Boegemann, M; Rahbar, K | 1 |
| Joensuu, T; Kairemo, K; Kiljunen, T; Roviello, G; Uprimny, C; Virgolini, I; von Eyben, FE | 1 |
| Aryana, K; Divband, G; Salek, R; Zarehparvar Moghadam, S | 1 |
| Ahmadzadehfar, H; Essler, M | 1 |
| Ahmadzadehfar, H; Albers, P; Bockisch, A; Boegemann, M; Böhme, C; Burchert, W; Dietlein, M; Drzezga, A; Essler, M; Fabry, U; Feldmann, G; Heidenreich, A; Heinzel, A; Herrmann, K; Heyll, A; Höhling, C; Kreuzer, C; Laufer, D; Mengel, R; Mottaghy, FM; Müller, HW; Müller, SC; Ost, E; Rahbar, K; Reifenhäuser, W; Schäfers, M; Schlenkhoff, C; Schmidt, M; Schmidt-Wolf, I; Wildenhain, C; Zimmer, B | 1 |
| Ahmadzadehfar, H; Bundschuh, RA; Eppard, E; Essler, M; Gaertner, FC; Khawar, A; Kürpig, S; Meisenheimer, M; Roesch, F; Sinnes, JP | 1 |
| Akhurst, T; Eu, P; Ferdinandus, J; Hicks, RJ; Hofman, MS; Iravani, A; Jackson, P; Kong, G; Murphy, DG; Ravi Kumar, A; Sandhu, S; Scalzo, M; Thang, SP; Violet, J; Williams, SG | 1 |
| Ahmadzadehfar, H; Essler, M; Gaertner, F; Lossin, PS; Schwarz, B | 1 |
| Cardaci, G; Kesavan, M; Lenzo, NP; Meyrick, D; Turner, JH; Yeo, S | 1 |
| Bögemann, M; Bräuer, A; Rahbar, K; Roll, W; Weckesser, M | 1 |
| Kim, YI; Kim, YJ | 1 |
| Ferretti, A; Gross, MD; Rubello, D; Viglianti, BL; Wale, DJ; Wong, KK | 1 |
| Gans, R; Lam, M; Stam, A; van Kalmthout, L | 1 |
| Banerjee, S; Basu, S; Joshi, A; Parghane, RV; Prabhash, K | 1 |
| Cooperberg, M; Eapen, RS; Hofman, MS; Lawrentschuk, N; Murphy, DG; Nzenza, TC | 1 |
| Blanksby, A; Crumbaker, M; Emmett, L; Epstein, R; Eu, P; Gedye, C; Guminski, A; Ho, B; Horvath, L; Joshua, AM; Mahon, K; Ratnayake, L; Stricker, P; Willowson, K; Yin, C | 1 |
| Baltzer, P; D'Andrea, D; Eidherr, H; Grubmüller, B; Grubmüller, KH; Hacker, M; Hartenbach, M; Haug, AR; Kramer, G; Mitterhauser, M; Pfaff, S; Senn, D; Shariat, SF; Wadsak, W | 1 |
| Barber, TW; Baum, RP; Billah, B; Kulkarni, HR; Niepsch, K; Singh, A | 1 |
| Belli, ML; Celli, M; Cittanti, C; Di Iorio, V; Ferrari, M; Mezzenga, E; Monti, M; Nicolini, S; Oboldi, D; Paganelli, G; Sarnelli, A; Severi, S; Tardelli, E; Uccelli, L | 1 |
| Aghdam, RA; Hashemifard, H; Norouzi, G; Pirayesh, E | 1 |
| Chen, X; Fan, X; Huo, L; Jacobson, O; Li, F; Lin, Y; Liu, Q; Niu, G; Wang, H; Wang, J; Zang, J; Zhu, Z | 1 |
| Bins, A; Braat, A; de Keizer, B; Hunting, J; Krijger, G; Lam, M; Mehra, N; van Kalmthout, L; van Leeuwaarde, R; Ververs, T | 1 |
| Bal, C; Ballal, S; Dwivedi, SN; Sahoo, RK; Yadav, MP | 1 |
| McBean, R; O'Kane, B; Parsons, R; Wong, D | 1 |
| Baum, RP; Kulkarni, HR; Singh, A; Zhang, J | 1 |
| D'Alessandria, C; Eiber, M; Gafita, A; Tauber, R; Wang, H; Weber, WA | 1 |
| Antonarakis, ES; Denmeade, SR; Eisenberger, MA; Eshleman, JR; Isaacsson Velho, P; Luo, J; Paller, CJ; Piana, D; Pomper, MG; Riel, S; Rowe, SP | 1 |
| Boerman, OC; Frielink, C; Goldenberg, DM; Lütje, S; McBride, WJ; Oyen, WJ; Sharkey, RM; van Rij, CM | 1 |
| AbuQbeitah, M; Aygün, A; Demirci, E; Kabasakal, L; Ocak, M; Toklu, T; Yeyin, N | 1 |
| Bodei, L; Ezziddin, S; Jilg, CA; Lassmann, M; Luster, M; Maecke, HR; Ohlmann, CH; Olbert, PJ; Pfestroff, A | 1 |
| Baum, RP; Klette, I; Kulkarni, HR; Mueller, D; Schottelius, M; Schuchardt, C; Singh, A; Wester, HJ; Wiessalla, S; Wirtz, M | 1 |
| Ahmadzadehfar, H; Eppard, E; Essler, M; Fimmers, R; Gärtner, F; Kürpig, S; Rogenhofer, S; Schlenkhoff, CD; Yordanova, A | 1 |
| Ahmadzadehfar, H; Essler, M; Gaertner, F; Schlenkhoff, CD; Schmidt, M | 1 |
| Ahmadzadehfar, H; Essler, M; Knüpfer, E; Schlenkhoff, CD | 1 |
| D'Alessandria, C; Eiber, M; Gschwend, JE; Heck, MM; Janssen, F; Maurer, T; Rauscher, I; Retz, M; Scheidhauer, K; Schottelius, M; Schwaiger, M; Storz, E; Tauber, R; Wester, HJ | 1 |
| Avramovic, N; Bode, A; Bögemann, M; Claesener, M; Rahbar, K; Stegger, L; Weckesser, M | 1 |
| Ahmadzadehfar, H; Bartenstein, P; Baum, RP; Fendler, WP; Heinzel, A; Heuschkel, M; Kratochwil, C; Krause, BJ; Lützen, U; Pfestroff, A; Prasad, V; Rahbar, K; Ruf, J; Schmidt, M | 1 |
| Ahmadzadehfar, H; Essler, M; Schlenkhoff, C; Sopora, C; Wei, X | 1 |
| Bartenstein, P; Böning, G; Delker, A; Fendler, WP; Gildehaus, FJ; Gratzke, C; Ilhan, H; Lehner, S; Reinhardt, S; Rominger, A; Stief, C | 1 |
| Bal, C; Ballal, S; Tripathi, M; Yadav, MP | 1 |
| Ahmadzadehfar, H; Bögemann, M; Rahbar, K | 1 |
| Bode, A; Bögemann, M; Rahbar, K; Roll, W; Weckesser, M | 1 |
22 review(s) available for lutetium and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Effects of
Topics: Actinium; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Leukopenia; Lutetium; Male; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Thrombocytopenia; Treatment Outcome; Xerostomia | 2022 |
[Efficacy and safety of the 177Lu-PSMA-617 therapy in the treatment of metastatic castration-resistant prostate cancer: A meta-analysis].
Topics: Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2021 |
Theragnostics in prostate cancer.
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Multicenter Studies as Topic; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2021 |
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2022 |
Hematologic toxicity profile and efficacy of [
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Kidney Diseases; Lutetium; Male; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2022 |
Lutetium Lu 177 Vipivotide Tetraxetan: First Approval.
Topics: Antineoplastic Agents; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Treatment Outcome | 2022 |
Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer.
Topics: Clinical Trials, Phase II as Topic; Dipeptides; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2022 |
Addressing the need for more therapeutic options in neuroendocrine prostate cancer.
Topics: Carcinoma, Neuroendocrine; Humans; Intracellular Signaling Peptides and Proteins; Lutetium; Male; Membrane Proteins; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radioisotopes | 2023 |
Lutetium Lu 177 vipivotide tetraxetan for prostate cancer.
Topics: Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
Emerging treatment options for prostate cancer.
Topics: Androgen Antagonists; Androgens; Docetaxel; Humans; Lutetium; Male; Prostatic Neoplasms, Castration-Resistant | 2023 |
[
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2023 |
[PSMA radioligand therapy in patients with advanced prostate cancer].
Topics: Dipeptides; Germany; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Treatment Outcome | 2020 |
A Walk with Lu-177 PSMA: How Close we Have Reached from Bench to Bedside?
Topics: Clinical Trials, Phase II as Topic; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Translational Research, Biomedical | 2020 |
Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration-Resistant Prostate Cancer Treated With 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy: A Systematic Review and Meta-analysis.
Topics: Antigens, Surface; Glutamate Carboxypeptidase II; Humans; Lutetium; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Treatment Outcome; Viscera | 2020 |
Novel therapies are changing treatment paradigms in metastatic prostate cancer.
Topics: Androgen Receptor Antagonists; Animals; Antineoplastic Agents; Clinical Trials as Topic; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Neoplasm Metastasis; Poly(ADP-ribose) Polymerase Inhibitors; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes | 2020 |
A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Treatment Outcome | 2021 |
[
Topics: Compassionate Use Trials; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2017 |
Third-line treatment and
Topics: Antigens, Surface; Glutamate Carboxypeptidase II; Humans; Ligands; Lutetium; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radioisotopes | 2018 |
Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis.
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Treatment Outcome | 2018 |
Nuclear Medicine Therapy With 223Radium-dichloride for Osseous Metastases in Prostate Carcinoma.
Topics: Bone Neoplasms; Clinical Trials as Topic; Humans; Lutetium; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radiotherapy; Radium | 2019 |
PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics.
Topics: Dipeptides; Gallium Isotopes; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Membrane Glycoproteins; Neoplasm Metastasis; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Theranostic Nanomedicine | 2019 |
Radioligand Therapy With
Topics: Humans; Lutetium; Male; Neoplasm Metastasis; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes | 2019 |
12 trial(s) available for lutetium and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Selective Intra-Arterial Lutetium-177-Labeled Prostate-Specific Membrane Antigen Therapy for Castration-Resistant Prostate Cancer: Initial Results.
Topics: Humans; Lutetium; Male; Neoplasm Metastasis; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Treatment Outcome | 2022 |
Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial.
Topics: Androgen Antagonists; Hormones; Humans; Lutetium; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes | 2021 |
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.
Topics: Adult; Dipeptides; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Receptors, Androgen; Taxoids; Treatment Outcome | 2023 |
The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy.
Topics: Dipeptides; Fluorodeoxyglucose F18; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
[
Topics: Dipeptides; Docetaxel; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Retrospective Studies; Survival Analysis; Treatment Outcome | 2023 |
Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for
Topics: Aged; Aged, 80 and over; Antigens, Surface; Dipeptides; Disease-Free Survival; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Treatment Outcome | 2019 |
Phase I/II Trial of the Combination of
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Treatment Outcome | 2021 |
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Kallikreins; Lutetium; Male; Middle Aged; Positron-Emission Tomography; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Survival Analysis | 2021 |
Circulating androgen receptor gene amplification and resistance to
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Dipeptides; Drug Resistance, Neoplasm; Gene Amplification; Heterocyclic Compounds, 1-Ring; Humans; Logistic Models; Lutetium; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Receptors, Androgen; Survival Analysis | 2021 |
[
Topics: Aged; Dipeptides; Disease Progression; Health Status; Heterocyclic Compounds, 1-Ring; Humans; Kallikreins; Lutetium; Male; Neoplasm Metastasis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radiopharmaceuticals; Time Factors; Treatment Outcome; Victoria | 2018 |
Results of a Prospective Phase 2 Pilot Trial of
Topics: Aged; Aged, 80 and over; Dipeptides; Disease Progression; Follow-Up Studies; Heterocyclic Compounds, 1-Ring; Humans; Image Processing, Computer-Assisted; Lutetium; Male; Middle Aged; Pilot Projects; Positron-Emission Tomography; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Survival Rate | 2019 |
Dosimetry of
Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Marrow; Dipeptides; Glutamic Acid; Half-Life; Heterocyclic Compounds, 1-Ring; Humans; Infusions, Intravenous; Kidney; Lutetium; Male; Mannitol; Middle Aged; Parotid Gland; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiation Dosage; Radioisotopes; Radiopharmaceuticals; Tablets | 2019 |
140 other study(ies) available for lutetium and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).
Topics: Aged; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Registries; Retrospective Studies; Treatment Outcome | 2022 |
Predicting outcomes after
Topics: Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostatic Neoplasms, Castration-Resistant | 2021 |
Excellent Response to Adapted Low-Dose 177Lu-PSMA-617 PSMA Therapy in Renal Compromise Patient.
Topics: Aged; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Kidney; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Treatment Outcome | 2022 |
Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?
Topics: Antigens, Surface; Antineoplastic Agents; Dipeptides; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Survival Analysis; Time-to-Treatment; Treatment Outcome; Tumor Burden | 2021 |
Tc-99m PSMA and Lu-177 PSMA Theranostic Pair in a Patient of Metastatic Castration Resistant Prostate Cancer.
Topics: Humans; Lutetium; Male; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Precision Medicine; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radioisotopes | 2021 |
Radiation Dose to Medical Staff from Administering
Topics: Humans; Lutetium; Male; Medical Staff; Prostatic Neoplasms, Castration-Resistant; Radiation Dosage; Radiopharmaceuticals; Treatment Outcome | 2022 |
In silico study on radiobiological efficacy of Ac-225 and Lu-177 for PSMA-guided radiotherapy.
Topics: Actinium; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Tumor Microenvironment | 2021 |
Treatment outcome and identification of factors influencing overall survival after Lu-177-PSMA-617 radioligand therapy in metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Retrospective Studies; Treatment Outcome | 2022 |
[Anticipating Criteria for Discharge after Lu-177-PSMA Treatment - Discussion of Several Scenarios].
Topics: Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Patient Discharge; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals | 2022 |
Lutetium-177-PSMA-617: A Vision of the Future.
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Treatment Outcome | 2022 |
A self-triggered radioligand therapy agent for fluorescence imaging of the treatment response in prostate cancer.
Topics: Antigens, Surface; Caspase 3; Dipeptides; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Optical Imaging; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2022 |
Periodontal Disease Association with Large-Artery Atherosclerotic Stroke.
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Matched-Pair Analysis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome; Urea | 2021 |
Topics: Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2022 |
Topics: Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2022 |
Delayed Nephrotoxicity After 225Ac-PSMA-617 Radioligand Therapy.
Topics: Actinium; Aged; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2022 |
Outcome of 177 Lu-PSMA Radionuclide Treatment in Advanced Prostate Cancer and Its Association With Clinical Parameters : A Single-Center Experience.
Topics: Alkaline Phosphatase; Hemoglobins; Heterocyclic Compounds, 1-Ring; Humans; Lactate Dehydrogenases; Lutetium; Male; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Retrospective Studies; Treatment Outcome | 2022 |
In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T.
Topics: Actinium; Cell Line, Tumor; Dipeptides; DNA; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes | 2022 |
Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond.
Topics: Humans; Lutetium; Male; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radiopharmaceuticals; Treatment Outcome | 2022 |
Outcome of Patients with PSMA PET/CT Screening Failure by VISION Criteria and Treated with
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2022 |
Prostate Cancer Treatment:
Topics: Clinical Trials, Phase III as Topic; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; United States | 2022 |
Extensive
Topics: Dipeptides; Humans; Kidney; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Thrombotic Microangiopathies; Treatment Outcome | 2023 |
EANM-EAU consensus on PSMA PET/CT in respect to radioligand therapy ([
Topics: Consensus; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2022 |
Stability Matters: Radiochemical Stability of Therapeutic Radiopharmaceutical
Topics: Humans; Lutetium; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Silica Gel | 2022 |
New Drug for Metastatic Castration-Resistant Prostate Cancer.
Topics: Antineoplastic Agents; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Treatment Outcome | 2022 |
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria.
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Reproducibility of Results; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2022 |
68 Ga-FAPI-46 PET/CT in a Metastatic Castration-Resistant Prostate Cancer Patient With Low PSMA Expression.
Topics: Aged; Dipeptides; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quinolines; Radioisotopes; Radiopharmaceuticals; Treatment Outcome | 2022 |
Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy.
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Liver Neoplasms; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Retrospective Studies | 2022 |
mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease.
Topics: Biomarkers, Tumor; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2022 |
Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy.
Topics: Antigens, Surface; Dipeptides; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survivors; Treatment Outcome | 2022 |
Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial.
Topics: Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Taxoids; Treatment Outcome | 2023 |
Systemic Therapy Update on
Topics: Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2022 |
Response to [ 177 Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases.
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Lymphatic Metastasis; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Retrospective Studies | 2022 |
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2023 |
Cross-reactivity to glutamate carboxypeptidase III causes undesired salivary gland and kidney uptake of PSMA-targeted small-molecule radionuclide therapeutics.
Topics: Antigens, Surface; Dipeptides; Glutamate Carboxypeptidase II; Humans; Kidney; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Salivary Glands | 2023 |
Genomic characterization of metastatic castration-resistant prostate cancer patients undergoing PSMA radioligand therapy: A single-center experience.
Topics: Aged; Dipeptides; DNA Helicases; Genomics; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
Safety and Survival Outcomes of
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome | 2023 |
A Single-Arm, Low-Dose, Prospective Study of
Topics: Androgen Antagonists; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Retrospective Studies; Treatment Outcome | 2023 |
Technical note: Investigating the suitability of existing facilities for a new Lu-177 prostate-specific membrane antigen therapy program.
Topics: Dipeptides; Humans; Lutetium; Male; Positron Emission Tomography Computed Tomography; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals | 2023 |
Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Topics: Cost-Benefit Analysis; Cost-Effectiveness Analysis; Dipeptides; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
Logistical, technical, and radiation safety aspects of establishing a radiopharmaceutical therapy program: A case in Lutetium-177 prostate-specific membrane antigen (PSMA) therapy.
Topics: Humans; Lutetium; Male; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Treatment Outcome | 2023 |
Systemic Therapy Update on
Topics: Dipeptides; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2023 |
Clinical Implementation of
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Longitudinal Studies; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; United States | 2023 |
Extended therapy with [
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
Peritoneal Metastases From Prostate Carcinoma Treated With 177 Lu-PSMA-I&T.
Topics: Aged; Carcinoma; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Peritoneal Neoplasms; Positron Emission Tomography Computed Tomography; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2023 |
Increased PSMA Expression in 177 Lu-PSMA-617 Scan in Metastatic Castrate-Resistant Prostate Cancer Patient Treated With PSMA Radioligand Therapy and Enzalutamide : A Potential Game-Changer.
Topics: Androgen Antagonists; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
New Horizons in Radioligand Therapy: 161Tb-PSMA-617 in Advanced mCRPC.
Topics: Aged, 80 and over; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Terbium; Treatment Outcome | 2023 |
PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials.
Topics: Dipeptides; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Treatment Outcome | 2023 |
Short-Interval, Low-Dose [ 177 Lu]Lu-Prostate-Specific Membrane Antigen in the Treatment of Refractory Glioblastoma.
Topics: Adult; Dipeptides; Glioblastoma; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Neoplasm Recurrence, Local; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Treatment Outcome | 2023 |
PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [
Topics: Dipeptides; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Reproducibility of Results; Retrospective Studies; Salivary Glands; Treatment Outcome | 2023 |
[New drugs approval: Lutetium-PSMA in metastatic castration-resistant prostate cancer].
Topics: Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Treatment Outcome | 2023 |
Synthesis of tritium-labeled Lu-PSMA-617: Alternative tool for biological evaluation of radiometal-based pharmaceuticals.
Topics: Dipeptides; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Pharmaceutical Preparations; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Tritium | 2023 |
Joint EANM/SNMMI procedure guideline for the use of
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Nuclear Medicine; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Treatment Outcome | 2023 |
SNMMI Consensus Statement on Patient Selection and Appropriate Use of
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Patient Selection; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes | 2023 |
Safety and Efficacy of [
Topics: Aged; Aged, 80 and over; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Octogenarians; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2023 |
PSMA-Negative Lesion Progression Under
Topics: Antigens, Surface; Dipeptides; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2023 |
The Tyr Phenomenon: A Hypocalcemic Response in High-Volume Treatment Responders to
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Hypocalcemia; Lutetium; Male; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
Re: Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. 2023;84:4-6.
Topics: Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Treatment Outcome | 2023 |
Tumor Volume on PSMA PET as a Prognostic Biomarker in Prostate Cancer Patients Treated With Cabazitaxel.
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Positron Emission Tomography Computed Tomography; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome; Tumor Burden | 2023 |
Urinary excretion kinetics of [
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals | 2023 |
Therapeutic efficacy and safety results of 177Lu-PSMA therapy in metastatic castration-resistant prostate cancer patients: first experience of a developing South Asian Country.
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2023 |
Long-term survival outcomes of salvage [
Topics: Aged; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
Early biochemical and radiographic response after one cycle of [
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
Excellent Response to Full-Dose 177 Lu-PSMA-617 RLT in Metastatic Castration-Resistant Prostate Cancer With Transplant Kidney : A Step Ahead.
Topics: Aged; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Kidney; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2023 |
Prediction of Resistance to
Topics: Circulating Tumor DNA; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2023 |
Treatment of Multiple Bone Metastases of Castration-Resistant Prostate Cancer With 225 Ac-PSMA-617.
Topics: Bone Neoplasms; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Treatment Outcome | 2023 |
Image-Guided Fine-Needle Aspiration Cytology for BRCA Mutation Assessment of PSMA-Positive Lymph Node Metastases in a Patient With Metastatic Castration-Resistant Prostate Cancer.
Topics: Biopsy, Fine-Needle; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Lymphatic Metastasis; Male; Middle Aged; Mutation; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals | 2023 |
Radioligand Therapy With 177 Lu-PSMA-I&T in Patients With Metastatic Prostate Cancer : Oncological Outcomes and Toxicity Profile.
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu-PSMA-617.
Topics: Aged; Humans; Inflammation; Lutetium; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2023 |
Topics: Animals; Glutamate Carboxypeptidase II; Isotope Labeling; Lutetium; Male; Mice; Molecular Weight; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiometry; Radiopharmaceuticals | 2019 |
Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Taxoids | 2019 |
PSMA radioligand therapy in prostate cancer: overview, latest advances and remaining challenges.
Topics: Antigens, Surface; Glutamate Carboxypeptidase II; Humans; Lutetium; Male; Prostatic Neoplasms, Castration-Resistant; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals | 2019 |
The value of tumor markers in men with metastatic prostate cancer undergoing [
Topics: Aged; Biomarkers, Tumor; Bone Neoplasms; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Kaplan-Meier Estimate; Lutetium; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Retrospective Studies; Survival Rate | 2020 |
Excellent Response to 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in a Patient With Progressive Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation After 177Lu-PSMA Therapy.
Topics: Aged; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Peptide; Treatment Outcome | 2019 |
Technical Note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in
Topics: Aged; Dipeptides; Feasibility Studies; Heterocyclic Compounds, 1-Ring; Humans; Kidney; Lutetium; Male; Organs at Risk; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiotherapy Planning, Computer-Assisted; Tomography, Emission-Computed, Single-Photon | 2019 |
Therapeutic efficacy, prognostic variables and clinical outcome of
Topics: Aged; Aged, 80 and over; Antigens, Surface; Dipeptides; Fluorodeoxyglucose F18; Gallium Radioisotopes; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Grading; Positron Emission Tomography Computed Tomography; Prognosis; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2019 |
Additional Local Therapy for Liver Metastases in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Systemic PSMA-Targeted Therapy.
Topics: Aged; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Liver Neoplasms; Lutetium; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Analysis | 2020 |
Prognostic importance of prostatic specific antigen response in patients who received Lutetium-177 prostate-specific membrane antigen treatment for castration resistant prostate cancer.
Topics: Dipeptides; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Positron Emission Tomography Computed Tomography; Prognosis; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Retrospective Studies; Treatment Outcome | 2021 |
Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Dipeptides; Edetic Acid; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2020 |
Posttherapeutic Critical Organ Dosimetry of Extensive 177Lu-PSMA Inhibitor Therapy With Metastatic Castration-Resistant Prostate Cancer: One Center Results.
Topics: Aged; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Organs at Risk; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiation Dosage; Radiopharmaceuticals; Radiotherapy Dosage | 2020 |
Early Prostate-Specific Antigen Changes and Clinical Outcome After
Topics: Aged; Antigens, Surface; Glutamate Carboxypeptidase II; Humans; Lutetium; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Retrospective Studies | 2020 |
Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617.
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Positron Emission Tomography Computed Tomography; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Eye Symptoms in a Patient With Prostate Cancer.
Topics: Aged; Dipeptides; Eye Neoplasms; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Single Photon Emission Computed Tomography Computed Tomography | 2020 |
Neuroendocrine Differentiation and Response to PSMA-Targeted Radioligand Therapy in Advanced Metastatic Castration-Resistant Prostate Cancer: A Single-Center Retrospective Study.
Topics: Antigens, Surface; Biomarkers; Cell Differentiation; Chromogranin A; Dipeptides; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Neuroendocrine Cells; Peptide Fragments; Phosphopyruvate Hydratase; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Recombinant Proteins | 2020 |
Influence of short-term dexamethasone on the efficacy of
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cohort Studies; Dexamethasone; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Retrospective Studies | 2020 |
A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2020 |
Efficacy and Safety of
Topics: Aged; Bone Marrow Neoplasms; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2020 |
Dose Calculations and Dose-Effect Relationships in 177Lu-PSMA I&T Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Dipeptides; Dose-Response Relationship, Radiation; Gallium Isotopes; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Membrane Glycoproteins; Middle Aged; Neoplasm Metastasis; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiation Dosage; Radiometry; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted | 2020 |
Whole-Body 177Lu-Prostate-Specific Membrane Antigen Scan Pattern With Excess Free 177Lu-Chloride in a Metastatic Castration-Resistant Prostate Cancer Patient.
Topics: Artifacts; Chlorides; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome; Whole Body Imaging | 2020 |
Estimation of [177Lu]PSMA-617 tumor uptake based on voxel-wise 3D Monte Carlo tumor dosimetry in patients with metastasized castration resistant prostate cancer.
Topics: Biological Transport; Humans; Lutetium; Male; Middle Aged; Monte Carlo Method; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiometry | 2020 |
Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving
Topics: Aged; Aged, 80 and over; Antigens, Surface; Biomarkers, Tumor; Chemoradiotherapy; Dipeptides; Follow-Up Studies; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Liver; Liver Neoplasms; Lutetium; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Prognosis; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiation Tolerance; Radiopharmaceuticals; Risk Assessment; Risk Factors; Survival Analysis; Treatment Outcome | 2020 |
Prediction of response and survival after standardized treatment with 7400 MBq
Topics: Aged; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2021 |
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | 2021 |
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
Topics: Actinium; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome; Xerostomia | 2021 |
Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with
Topics: Aged; Aged, 80 and over; Antigens, Surface; Glutamate Carboxypeptidase II; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Retrospective Studies; Treatment Outcome | 2021 |
Response to Concomitant Enzalutamide and 177Lu-PSMA-617 Radioligand Therapy in ATM-Mutated Metastatic Castration Resistant Prostate Cancer.
Topics: Aged; Benzamides; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2021 |
Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients.
Topics: Aged; Antigens, Surface; Glutamate Carboxypeptidase II; Humans; Lutetium; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radiation Tolerance; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Treatment Outcome | 2021 |
A perspective on the EANM procedure guidelines for radionuclide therapy with
Topics: Dipeptides; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes | 2021 |
Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes | 2021 |
Topics: Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Nuclear Medicine; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2021 |
Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Retrospective Studies; Survival Analysis; Treatment Outcome | 2017 |
Topics: Aged; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Safety; Survival Analysis; Treatment Outcome | 2017 |
Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer.
Topics: Aged; Brain Neoplasms; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Positron Emission Tomography Computed Tomography; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2017 |
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2017 |
PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.
Topics: Aged; Antigens, Surface; Dipeptides; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Survival Analysis | 2018 |
Delayed response after repeated
Topics: Adult; Aged; Aged, 80 and over; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Time Factors; Treatment Outcome | 2018 |
Topics: Clinical Trials, Phase III as Topic; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant | 2018 |
177Lu-Prostate-Specific Membrane Antigen Super Scan and Good Response Even After 1 Cycle of Radioligand Therapy.
Topics: Aged; Biological Transport; Bone Neoplasms; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Kidney; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiotherapy Dosage; Treatment Outcome; Whole Body Imaging | 2018 |
Predictive Factors of Response and Overall Survival in Patients with Castration-Resistant Metastatic Prostate Cancer Undergoing
Topics: Antigens, Surface; Glutamate Carboxypeptidase II; Humans; Lutetium; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Survival Analysis | 2018 |
[Lutetium-177-PSMA radioligand therapy : Consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Düsseldorf, Essen, and Cologne and the MDK Nordrhein].
Topics: Antigens, Surface; Consensus; Germany; Health Care Costs; Hospitals, University; Humans; Insurance, Health; Insurance, Health, Reimbursement; Ligands; Lutetium; Male; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Treatment Outcome | 2018 |
Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma.
Topics: Aged; Carcinoma; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Neoplasm Metastasis; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiation Dosage; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Scandium | 2018 |
BRCA2 Mutation as a Possible Cause of Poor Response to 177Lu-PSMA Therapy.
Topics: Aged; BRCA2 Protein; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Mutation; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2018 |
Salvage Radiopeptide Therapy of Advanced Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen: Efficacy and Safety in Routine Practice.
Topics: Aged; Aged, 80 and over; Antigens, Surface; Glutamate Carboxypeptidase II; Humans; Kallikreins; Lutetium; Male; Middle Aged; Neoplasm Staging; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2018 |
Long-term Survival and Excellent Response to Repeated 177Lu-Prostate-Specific Membrane Antigen 617 Radioligand Therapy in a Patient With Advanced Metastatic Castration-Resistant Prostate Cancer.
Topics: Aged; Dipeptides; Disease-Free Survival; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Male; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2018 |
Visual deficit possibly caused by lutetium-177 PSMA treatment.
Topics: Bone Neoplasms; Diagnosis, Differential; Humans; Lutetium; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radiation Injuries; Radioisotopes; Radiopharmaceuticals; Vision Disorders | 2018 |
The rationality of combining second-generation antiandrogens with 177Lu-PSMA or its alpha-emitting congeners for better and durable results: will this dominate the therapeutic landscape and be an upfront consideration in metastatic castration-resistant pr
Topics: Alpha Particles; Androgen Antagonists; Antigens, Surface; Combined Modality Therapy; Glutamate Carboxypeptidase II; Humans; Lutetium; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Treatment Outcome | 2018 |
Response assessment using
Topics: Aged; Dipeptides; Follow-Up Studies; Gallium Isotopes; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Male; Membrane Glycoproteins; Neoplasm Metastasis; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; ROC Curve; Survival Analysis; Treatment Outcome | 2019 |
Clinical Outcomes of
Topics: Aged; Aged, 80 and over; Bridged-Ring Compounds; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Male; Neoplasm Metastasis; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Safety; Taxoids; Time Factors; Treatment Outcome | 2019 |
Excellent Response to Lower Dose of 177Lu-PSMA-617 in a Metastatic Castration-Resistant Prostate Cancer Patient With a Transplanted Kidney.
Topics: Aged; Bone Neoplasms; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals | 2019 |
Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions.
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Retrospective Studies; Single Photon Emission Computed Tomography Computed Tomography; Whole Body Imaging | 2019 |
First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands.
Topics: Aged; Aged, 80 and over; Analgesics; Antineoplastic Agents; Dipeptides; Fatigue; Follow-Up Studies; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Netherlands; Pain; Pain Measurement; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome; Xerostomia | 2019 |
Lu177-PSMA therapy for men with advanced prostate cancer: Initial 18 months experience at a single Australian tertiary institution.
Topics: Aged; Aged, 80 and over; Australia; Follow-Up Studies; Humans; Lutetium; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Tertiary Care Centers; Treatment Outcome | 2019 |
Complete Regression of Lung Metastases in a Patient With Metastatic Castration-Resistant Prostate Cancer Using 177Lu-PSMA Radioligand Therapy.
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lung Neoplasms; Lutetium; Lymphatic Metastasis; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2020 |
Exceptional 4-year response to
Topics: Aged; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals | 2019 |
A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Antigens, Surface; Bridged-Ring Compounds; Dipeptides; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; RNA, Messenger; Taxoids; Treatment Outcome | 2019 |
Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a (177)Lu-Labeled Peptide.
Topics: Animals; Antibodies, Bispecific; Antigens, Neoplasm; Cell Adhesion Molecules; Cell Line, Tumor; Humans; Immunotoxins; Lutetium; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Hormone-Dependent; Oligopeptides; Prostatic Neoplasms, Castration-Resistant; Radioimmunotherapy; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Xenograft Model Antitumor Assays | 2014 |
Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.
Topics: Aged; Antigens, Surface; Bone Marrow; Dipeptides; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Kidney; Lutetium; Male; Middle Aged; Organs at Risk; Parotid Gland; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radiotherapy Dosage | 2015 |
Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks.
Topics: Antigens, Surface; Clinical Trials as Topic; Docetaxel; Europe; Glutamate Carboxypeptidase II; Humans; Ligands; Lutetium; Male; Oligopeptides; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Taxoids | 2015 |
177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
Topics: Aged; Antigens, Surface; Cohort Studies; Dipeptides; Disease-Free Survival; Edetic Acid; Erythrocyte Count; Gallium Isotopes; Gallium Radioisotopes; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Leukocyte Count; Lutetium; Male; Neoplasm Metastasis; Oligopeptides; Organometallic Compounds; Pain; Patient Selection; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiometry; Radiopharmaceuticals; Treatment Outcome | 2016 |
Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Organometallic Compounds; Peptides; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Retrospective Studies | 2016 |
Positive Influence of 177Lu PSMA-617 Therapy on Bone Marrow Depression Caused by Metastatic Prostate Cancer.
Topics: Aged; Anemia; Antineoplastic Agents; Bone Marrow Diseases; Bone Neoplasms; Compassionate Use Trials; Dipeptides; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Oligopeptides; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Radium; Technetium Tc 99m Medronate | 2016 |
Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617.
Topics: Aged, 80 and over; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Treatment Outcome | 2016 |
Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer.
Topics: Adenocarcinoma; Aged; Antigens, Surface; Glutamate Carboxypeptidase II; Humans; Ligands; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome | 2016 |
Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Antigens, Surface; Dipeptides; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Regression Analysis; Retrospective Studies; Survival Analysis | 2016 |
[177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer].
Topics: Dipeptides; Follow-Up Studies; Germany; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Nuclear Medicine; Practice Guidelines as Topic; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiation Dosage; Radiometry; Radiopharmaceuticals; Treatment Outcome | 2016 |
Successful Treatment of Hepatic Metastases of Hormone Refractory Prostate Cancer Using Radioligand Therapy With 177Lu-PSMA-617.
Topics: Aged, 80 and over; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Liver Neoplasms; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals | 2016 |
Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Combined Modality Therapy; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Patient Reported Outcome Measures; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiometry; Retreatment | 2017 |
Reply to Rahbar K et al.
Topics: Bone Neoplasms; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Outcome Assessment, Health Care; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radiotherapy; Treatment Outcome | 2017 |
Topics: Bone Neoplasms; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Outcome Assessment, Health Care; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Radiotherapy; Treatment Outcome | 2017 |
Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Surface; Dipeptides; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Organometallic Compounds; Peptides; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Whole Body Imaging; Whole-Body Counting | 2017 |
Excellent Response to 177Lu-PSMA-617 Radioligand Therapy in a Patient With Advanced Metastatic Castration Resistant Prostate Cancer Evaluated by 68Ga-PSMA PET/CT.
Topics: Aged; Bone Neoplasms; Dipeptides; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Oligopeptides; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals | 2017 |